In today's world, Org 28312 has gained unprecedented relevance. Whether in the field of politics, science, culture or technology, Org 28312 has become a topic of constant interest and debate. Knowing more about Org 28312 and its implications is crucial to understanding the current landscape and the trends that are setting the course for the future. In this article we will explore the various facets of Org 28312, from its origin to its impact on today's society, to offer a complete and updated view of this phenomenon.
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H35N3O2 |
Molar mass | 397.563 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Org 28312 is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suitable for intravenous use as an analgesic, but did not proceed to human trials, with the related compound Org 28611 chosen instead due to its better penetration into the brain.[1] The structure-activity relationships of these compounds have subsequently been investigated further leading to the development of a number of more potent analogues, derived by cyclisation around the indole or piperazine rings.[2][3]